Upperton Pharma Solutions

Upperton Pharma Solutions is a specialist CDMO (contract development and manufacturing organization) providing formulation and dosage form development and clinical trial manufacturing services to the biotechnology and pharmaceutical industries. The company offers a complete development service, from early feasibility studies to process optimization, scale up, and clinical trial (GMP/IMP) manufacturing. Upperton Pharma Solutions has expertise in utilizing an extensive range of formulation technologies, with a focus on pharmaceutical spray dryings. This expertise positions them as a leader in an industry that heavily relies on this technology. The company's experience spans a range of dosage forms, reaffirming their capability to develop challenging molecules. Their formulation work is supported by a comprehensive range of analytical services for product testing and ICH stability studies. Founded in 1999 and headquartered in the United Kingdom, Upperton Pharma Solutions has built an extensive, multinational client base, catering to virtual and small start-ups as well as global pharma companies. The company's client-focused, flexible approach and scientific excellence have been pivotal in their success. The most recent investment in Upperton Pharma Solutions was a Private Equity Round investment on 21 April 2022, with the investment coming from Inflexion Partners. This injection of capital reflects the industry's recognition of Upperton Pharma Solutions' potential to further drive innovation and support the pharmaceutical and biotechnology sectors.